Can gender predict virological response to standard antiviral therapy for chronic hepatitis C? A retrospective study

Abstract

Aim: The liver is a sexually dimorphic organ presenting gender differences in its metabolism, functions, enzyme activity, membrane lipid composition and immune response. This paper aimed to assess whether gender may predict virological response to standard antiviral therapy in subjects with chronic hepatitis C (CHC).

Methods: The authors retrospectively analyzed 100 patients with genotype 1 CHC (55 men, 45 women), who performed standard antiviral therapy (interferon and ribavirin for 12 months) in the period 2002-2012, evaluated with blood tests and abdominal ultrasound to compare different virological and biochemical response in both gender.

Results: Rate of substained virological response (SVR) was higher, but not significant, in women than men (46.7% vs. 34.5%, P = 0.05); difference became significant after stratification by age (< 50 and ≥ 50 years). Specifically in the group aged under 50 years, rate of SVR was significantly higher in women than in men (66.7% vs. 38.2%, P < 0.05).

Conclusion: Female gender may predict virological response to standard antiviral therapy in subjects with CHC aged below 50 years. Considering new potent and more expensive antiviral drugs actually available for HCV treatment, it could be useful to identify candidates firstly eligible to therapy.

Keywords

Liver / gender / antiviral therapy

References

[1] Yokoyama Y,Nagino M,Chaudry IH.Current understanding of gender dimorphism in hepatic pathophysiology..J Surg Res2005;128:147-56

[2] Shimizu I,Tamaki K,Huang HW,Yao DF.Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection..World J Gastroenterol2007;13:4295-305 PMCID:PMC4250853

[3] Ismail N,Smith MB.Laboratory evaluation of a fully automated chemiluminescence immunoassay for rapid detection of HBsAg, antibodies to HBsAg, and antibodies to hepatitis C virus..J Clin Microbiol2004;42:610-7 PMCID:PMC344481

[4] Jonas G,Beckert C,Kapprell HP.Performance characteristics of the ARCHITECT anti-HCV assay..J Clin Virol Off Publ Pan Am Soc Clin Virol2005;34:97-103

[5] Krajden M,Khan A,Leung K.Qualitative detection of hepatitis C virus RNA: comparison of analytical sensitivity, clinical performance, and workflow of the Cobas Amplicor HCV test version 2.0 and the HCV RNA transcription-mediated amplification qualitative assay..J Clin Microbiol2002;40:2903-7 PMCID:PMC120657

[6] Pittaluga F,Abate ML,Cerutti F,Colucci G,Ghisetti V.Clinical evaluation of the COBAS Ampliprep/COBAS TaqMan for HCV RNA quantitation in comparison with the branched-DNA assay..J Med Virol2008;80:254-60

[7] Elbeik T,Destree M,Holodniy M,Kuramoto K,Valdes RJr,Terrault NA.Multicenter evaluation of the performance characteristics of the bayer VERSANT HCV RNA 3.0 assay (bDNA)..J Clin Microbiol2004;42:563-9 PMCID:PMC344448

[8] Sizmann D,Boelter J,Miethke M,Zadak M.Fully automated quantification of hepatitis C virus (HCV) RNA in human plasma and human serum by the COBAS AmpliPrep/COBAS TaqMan system..J Clin Virol2007;38:326-33

[9] Nolte FS,Fiebelkorn KR,Sturchio C,Healy M.Clinical evaluation of two methods for genotyping hepatitis C virus based on analysis of the 5' noncoding region..J Clin Microbiol2003;41:1558-64 PMCID:PMC153875

[10] Armstrong MJ,Hodson J,Parker R,Rowe IA,Brown R,Mutimer D.Operator training requirements and diagnostic accuracy of Fibroscan in routine clinical practice..Postgrad Med J2013;89:685-92 PMCID:PMC3841754

[11] Codes L,Cazals-Hatem D,Vidaud D,Bedossa P,Marcellin P.Liver fibrosis in women with chronic hepatitis C: evidence for the negative role of the menopause and steatosis and the potential benefit of hormone replacement therapy..Gut2007;56:390-5 PMCID:PMC1856786

[12] Fierbinţeanu-Braticevici C,Tribus L,Creţoiu SM,Usvat R.Hepatocyte steatosis in patients infected with genotype 1 hepatitis C virus..Romanian J Morphol Embryol2010;51:235-42

[13] Villa E,Cammà C,Luongo M,Petta S,Taliani G,Lei B,Bernabucci V,Pazienza P,Antonelli A.Early menopause is associated with lack of response to antiviral therapy in women with chronic hepatitis C..Gastroenterology2011;140:818-29

[14] Rigamonti C,Maduli E,Boldorini R.Gender and liver fibrosis in chronichepatitis: the role of iron status..Aliment Pharmacol Ther2005;21:1445-51

[15] Lao XQ,McHutchison JG.Sex and age differences in lipid response to chronic infection with the hepatitis C virus in the United States National Health and Nutrition Examination Surveys..J Viral Hepat2011;18:571-9

[16] Bakr I,El Hosseiny M,El Daly M,Esmat G,Mohamed MK.Higher clearance of hepatitis C virus infection in females compared with males..Gut2006;55:1183-7 PMCID:PMC1856273

[17] Aziz H,Waheed Y,Raza A,Athar MA.Evaluation of prognostic factors for Peg Interferon alfa-2b plus ribavirin treatment on HCV infected patients in Pakistan..Infect Genet Evol2011;11:640-5

[18] Idrees M.A study of best positive predictors for sustained virologic response to interferon alpha plus ribavirin therapy in naive chronic hepatitis C patients..BMC Gastroenterol2009;9:5 PMCID:PMC2651183

[19] Yu JW,Zhao YH,Yan BZ.Impact of sex on virologic response rates in genotype 1 chronic hepatitis C patients with peginterferon alpha-2a and ribavirin treatment..Int J Infect Dis2011;15:e740-6

[20] Akram M,Zafar S,Butt S,Rehman IU,Saleem S,Butt A.Effects of host and virus related factors on interferon-α+ribavirin and pegylated-interferon+ribavirin treatment outcomes in chronic Hepatitis C patients..Virol J2011;8:234 PMCID:PMC3113307

[21] Villela-Nogueira CA,de SegadasSoares JA.Gamma-glutamyltransferase (GGT) as an independent predictive factor of sustained virologic response in patients with hepatitis C treated with interferon-alpha and ribavirin..J Clin Gastroenterol2005;39:728-30

[22] Hu CC,Kuo YL,Chen SW,Lin CY.Efficacy and safety of ribavirin plus pegylated interferon alfa in geriatric patients with chronic hepatitis C..Aliment Pharmacol Ther2013;37:81-90

[23] Innes HA,Allen S,Bramley P,Delahooke TE,Goldberg DJ,Mills PR,Morris J,Stanley AJ.Ranking predictors of a sustained viral response for patients with chronic hepatitis C treated with pegylated interferon and ribavirin in Scotland..Eur J Gastroenterol Hepatol2012;24:646-55

[24] Floreani A,Boemo DG,Baldo V,Antoniazzi S.Female patients in fertile age with chronic hepatitis C, easy genotype, and persistently normal transaminases have a 100% chance to reach a sustained virological response..Eur J Gastroenterol Hepatol2011;23:997-1003

[25] Aziz H,Murtaza S,Waheed Y,Raza A.Predictors of response to antiviral therapy in patients with chronic hepatitis C from Pakistani population..Chin Med J (Engl)2011;124:1333-7

[26] Hayashi J,Ueno K,Kawakami Y,Sawayama Y.Age-related response to interferon alfa treatment in women vs men with chronic hepatitis C virus infection..Arch Intern Med1998;158:177-81

[27] Sezaki H,Kawamura Y,Hosaka T,Kobayashi M,Saitoh S,Ikeda K,Kumada H.Poor response to pegylated interferon and ribavirin in older women infected with hepatitis C virus of genotype 1b in high viral loads..Dig Dis Sci2009;54:1317-24

[28] Villa E,Di Leo A,Enea M,Bernabucci V,De Maria N,Ferrari A,Vignoli P,Francavilla A.Peginterferon-Α_2B plus ribavirin is more effective than peginterferon-Α_2A plus ribavirin in menopausal women with chronic hepatitis C..J Viral Hepat2012;19:640-9